Attorney Docket No.: 270/070 (UMD-0070)

Inventors:

Langenfeld, John

Serial No.:

10/044,716

Filing Date:

January 11, 2002

Page 3

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

Claim 1 (currently amended): A method for the treatment of lung cancer comprising administering to a patient with lung cancer a therapeutically effective amount of a noggin, chordin, gremlin, cerberus 1 homolog, or DAN polypeptide that binds specifically to a to antagonize binding of bone morphogenetic protein-2 (BMP-2) so that to BMP-2 receptor activation is prevented thereby treating the lung cancer.

Claims 2-5 (canceled).

Claim 6 (currently amended): The method of claim 1 wherein the noggin polypeptide that binds specifically to BMP 2 is human noggin of SEQ ID NO:4.

Claims 7-16 (canceled).

Claim 17 (original): The method of claim 1 wherein the patient is a human.

Claim 18 (currently amended): The method of claim 1 wherein the polypeptide that binds specifically to BMP 2 is composition further comprising a pharmaceutically acceptable carrier.

Attorney Docket No.:

270/070 (UMD-0070) Langenfeld, John

Inventors:

10/044,716

Serial No.:
Filing Date:

January 11, 2002

Page 4

Claim 19 (currently amended): The method of claim 18 wherein the polypeptide that binds specifically to BMP 2 is administered orally, enterically, intravenously, peritoneally, subcutaneously, transdermally, parenterally, intratumorally, or rectally.

Claims 20-64 (canceled).